Quintiles expands kidney disease trial offering with DaVita deal

Quintiles ($Q) has teamed up with kidney care specialist DaVita Clinical Research in a deal designed to help shore up offerings in renal disease clinical trials.

DaVita Clinical Research, part of DaVita Healthcare Partners, is a major healthcare player, working with more than one million patients--patients that can be sought for clinical trials.

In a joint statement, both companies point out the studies for patients with kidney problems are becoming more complex in terms of how they are put together, while biopharmas are calling for broader patient populations.

Infographic Download

Reducing Time to Clinic for Your Biomedical Applications

Gelatin methacryloyl (GelMA)-based biomaterials have been widely used in various biomedical research applications due to their suitable biological properties and tunable physical characteristics. Especially over the past 5 years, GelMA-oriented research and patent applications have been growing exponentially, and many of these research concepts are now being translated towards the clinic. Suitable GelMA biomaterials are therefore indispensable to keep pace with the newest medical innovations.

Download to learn more about the benefits of GelMA in various biomedical applications and how X-Pure® GelMA can help you in your developments.

In this collab, financial details of which were not disclosed, the two companies said they will come together in order to: “Provide capabilities and solutions for overcoming these challenges to deliver end-to-end support for renal disease clinical trials.”

They added in a statement: “By leveraging Quintiles’ protocol modeling and feasibility, in combination with DaVita’s extensive patient understanding, biopharmaceutical customers will be able to take advantage of the combined assets of both companies to progress their clinical programs.”

Amy Young, VP and general manager of DaVita Clinical Research, said: “This alliance allows novel approaches to clinical development and clinical trial execution specifically in site identification, participant enrollment and study design. We are excited about the opportunities this affords our organizations to provide innovative solutions to the biopharmaceutical industry and the participants we serve.”

- check out the release

Related Articles:
Quintiles, IMS Health unveil surprise megamerger
Quintiles bets on a big 2016 as revenue rolls in


Suggested Articles

CTI Clinical Trial and Consulting Services is buying up fellow CRO Clinart to deepen its reach in the Middle Eastern and Northern African regions.

Viva Biotech is putting down $80 million to buy preclinical contract research organization SYNthesis and boost its outsourcing business.

Popular research network provider TriNetX has seen major interest from The Carlyle Group as it buys up a majority stake in the company.